Hohnloser SH, et al. - Among patients with atrial fibrillation who were randomized to apixaban or warfarin for stroke prevention in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; n=18,201) randomized trial, researchers performed this post hoc analysis to approximate the randomized treatment impact (apixaban vs warfarin) stratified by body weight (≤60, >60–120, >120 kg) and assessed if there was any relationship between body weight and randomized treatment. Across all weight groups, including low- (≤60 kg) and high-weight patients (>120 kg), apixaban's superior effectiveness and safety were evident vs warfarin. Even greater decreases in major bleeding in patients with atrial fibrillation were seen in low to normal weight vs high weight patients. A similarity was noted for the superior effectiveness and safety of apixaban vs warfarin for stroke prevention, so apixaban seemed to be suitable for patients with atrial fibrillation regardless of body weight.